Sanofi Bids €308m To Buy Kiadis
Premium of 272%
Arthur Lahr, CEO of the Dutch biotech, said the offer is testimony to the uniqueness of the firm's natural killer (NK) cell platform "and the rapid success of Kiadis’s transformation."
You may also be interested in...
Sanofi R&D head John Reed says company has kept 95% of patients on its nearly 400 clinical trials and started 59 studies. Company has also stepped up collaborations and closed acquisitions, integrating employees remotely.
Deal Snapshot: Pharma places $30m upfront wager on biotech’s allogeneic natural killer cell and chimeric antigen receptor technologies, with hopes for solid tumor cell therapies.
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Novartis explains its PD-1 deal; Biogen partners with Apple; Sanofi and Merck discuss business development priorities; and why AbbVie is confident it can grow without relying on deals.